7 recruiting. 7 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Recruiting 7 |
| Phase 2 | 2 | Recruiting 2 |
Follow RAS Mutation: new trials by email Literature Review of RAS Mutation trials Research Report on RAS Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression Intravenous AN4035, Intravenous AN4035 followed by intravenous EGFR Inhibitor. - Solid Tumor (Phase I), RAS Mutation | Phase 1 | Recruiting | Adlai Nortye Biopharma Co., Ltd. | 228 | 2026-09-23 | 2026-10-16 |
| A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations BG-85738, Tislelizumab, Cetuximab - RAS Mutation, Advanced Solid Tumor | Phase 1 | Recruiting | BeOne Medicines | 100 | 2026-09-02 | 2026-10-23 |
| A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation GFH276, Cetuximab, Nab paclitaxel - Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Genfleet Therapeutics (Shanghai) Inc. | 222 | 2026-09-01 | 2026-10-05 |
| Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations AN9025 oral capsule - Solid Tumors (Phase 1), RAS Mutation | Phase 1 | Recruiting | Adlai Nortye Biopharma Co., Ltd. | 118 | 2026-01-28 | 2026-06-08 |
| Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients TNG462, RMC-9805, RMC-6236 - PDAC, PDAC - Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Tango Therapeutics, Inc. | 183 | 2025-05-31 | 2026-10-23 |
| PAS-004 in Patients With Advanced Solid Tumors PAS-004 Capsules, PAS-004 Tablets - RAS Mutation, NF1 Mutation | Phase 1 | Recruiting | Pasithea Therapeutics Corp. | 83 | 2024-02-29 | 2026-10-30 |
| A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies RSC-1255 Dose Escalation, RSC-1255 Dose Expansion - Advanced Malignant Solid Neoplasm, RAS Mutation | Phase 1 | Recruiting | RasCal Therapeutics, Inc. | 134 | 2021-03-03 | 2026-06-23 |
Lung Neoplasms (2) · Neoplasms (2) · Colonic Neoplasms (1) · Disease Progression (1) · Glioblastoma (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1)
Lung Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Thoracic Neoplasms (2) · Astrocytoma (1) · Colonic Diseases (1) · Colorectal Neoplasms (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Disease Attributes (1) · Endocrine Gland Neoplasms (1)
Cetuximab (2) · Fluorouracil (1) · Gemcitabine (1) · Irinotecan (1) · Leucovorin (1) · Oxaliplatin (1) · Taxes (1) · tislelizumab (1)
Adlai Nortye Biopharma Co., Ltd. (2) · BeOne Medicines (1) · Genfleet Therapeutics (Shanghai) Inc. (1) · Pasithea Therapeutics Corp. (1) · RasCal Therapeutics, Inc. (1) · Tango Therapeutics, Inc. (1)
United States (4) · Australia (3) · Bulgaria (1) · China (1) · New Zealand (1) · Romania (1)
Kartik Krishnan, MD, PhD (1) · Maxim Pimpkin, MD, PhD (1) · Michael Mann, MD (1)